Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
that's old news ...any new news of substance?
Go PMCB!!!
I feel the vibe too CI...but for now, until we get the box checked, we're still on the outside looking in.
Go big John!!!
Perhaps CI was just glad to know that there are no plans for another system per HC
that's just theater ...why even pay attention to something so ridiculous
Overlooked, sorry :) .. Have a great weekend!
Not me! ...I feel good as I ever did about KW and my investment ...I'll hold till the cows come home :)
Oh, I know it's definitely coming ;) ...that's what keeps me excited
There is the possibility of still having to wait the extended seed time ... I just hope we've exceeded that period.
New PR has no meat...just another discussion
Go KW!!!
lol ...PLEASE!!!...keep looking!
Do you really think that this news was "just announced"?
Go big John!!!
Probably not much more than after March 17th's volume
Go KW!!!
I am too buddy
But we won't, at least not until we get the box checked Madd ....not a minute sooner imo
Let's go big John!!!!
Rudy, with regards to the double blinded trial, is it the patient and PMCB that doesn't know?, or the patient and the administering doctors that doesn't know?
News! ...You gonna buy another million shares today Pete?....to add to your Gazillion!!!?
Go KW!!!
UNC is submitting abstracts of two scientific papers of their work with cannabinoids and CiaB. I'm hoping we get an encouraging new broad-based information report. Would love the momentum to pick up on this front.
Go KW!!!!
The ACS National Meeting provides chemistry professionals a forum to meet, share ideas and advance scientific and technical knowledge. The theme of the upcoming meeting is “Advanced Materials, Technologies, Systems & Processes.” PharmaCyte’s Cannabis research at UNC fits the theme perfectly since it revolves around utilization of PharmaCyte’s proprietary Cell-in-a-Box® technology. The papers will be presented by Dr. Richard M. Hyslop, Principal Investigator and Professor of Chemistry and Biochemistry at UNC and his students.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented “We are very pleased with the ongoing progress at UNC. The upcoming ACS meeting provides an ideal venue to present two more scientific papers that have been generated from the work being done by Dr. Hyslop and his team as well as showcase the versatility of Cell-in-a-Box® as an advanced therapeutic platform.”
The first paper is titled “Development of a cannabinoid-based Cell-in-a-Box® therapeutic system targeted toward malignant tumors.” This aspect of the UNC research investigates the feasibility of a patented cell-encapsulation technology in which cells producing enzymes capable of converting an inactive phytocannabinoid prodrug into an active anti-cancer drug are encapsulated in a cellulose-based porous polymer, which can be injected immediately upstream from a tumor. Then, an administered phytocannabinoid prodrug can be activated by the encapsulated cells at the site of the tumor. The paper describes how, using both specific phytocannabinoids and model compounds, a variety of cell lines have been screened for the appropriate enzymatic activity to convert an inactive cannabinoid prodrug into an active drug. Five cell lines have been observed to produce the desired enzyme and are being further assessed with specific phytocannabinoid prodrugs.
The second paper is titled “In vitro anti-neoplastic activity of specific phytocannabinoids of Cannabis sativa.” As part of a more in-depth study to develop a cannabinoid-based targeted treatment of malignant tumors, the in vitro effects of select cannabinoids on several human cancer cell lines have been investigated, including glioblastoma, pancreatic, breast, melanoma, lung and colon. The paper describes how single-cell layer cultures were treated with increasing levels of a purified cannabinoid and details the resultant changes in cancer cell populations. Initial results suggest that this cannabinoid possesses potent anti-proliferative effects against several types of cancer cells. Studies continue to assess this cannabinoid with several cancer cell lines, and it may represent a viable candidate for further therapeutic evaluation.
Dr. Hyslop has been involved in cancer research for four decades and is leading a team of scientists from UNC to develop a “green” approach to treating solid tumors, initially brain cancer. “We are looking forward to sharing some of our results with the scientific community,” commented Dr. Hyslop. “Our team of biochemists, organic chemists, molecular biologists, genetic engineers, undergraduate students, and graduate students continue to work diligently to achieve our goal of developing targeted cannabinoid-based chemotherapy utilizing Cell-in-a-Box®.”
Go KW!!!!!
lol You keep saying that to yourself.
CiaB tech has always been a mere tool...a way to administer.
It is the drugs and therapy utilizing CiaB of which a company has to be "successful" with.
Success that PMCB will prove soon enough to all you naysayers.
Go KW!!!
If that post doesn't give anyone the perspective of just how close we really are then nothing will ;)
Thanks Rudy
Go KW!!!!!!!!
lol ... you know damn good and well that in this process "20 months" ago is like yesterday
During one of HC's last press, "...the last day of Spring is June 21st" was reiterated when explaining their ongoing efforts, as if to say they will possibly take that long before commencement.
Our patience with both the "sales" and legalization will pay off eventually.
Go big John!!!
You can say that again!
As expected...
Moving forward with old patent, with "rewritten" design, IS NOT possible/allowed ....so, due to the suggested changes by the FDA the new filing is necessary.
The new patent application, or "provisional", is a one year time clock that allows them ample time to redesign/rewrite and perfect.
This is great news.
GoPMCB!!! Go KW!!!
I agree ...having the patience and understanding of the tasks charged to PharmaCyte, Austrianova, TD2 and the others is important. Sure glad all entities are on the same page now and moving forward.
Go PMCB!!!
lol ...hook, line, and sinker
yeah right!!! ...cuz thats going to happen lol
...but not the "therapy" for which it is being utilized...your DD is not complete
BULLSHIT?! ...what is bullshit is your post claiming facts contrary to the previous milestoneswhat that have come to fruition.
right! ...just like to facts you posted many times before all previous milestones
Rudy, that would be great, but if that was the case he probably would've done a PR then rather than today, don't you think?
Go PMCB!!!
PharmaCyte Biotech, Inc. PharmaCyte is undertaking steps to insure its has patent protection for its cancer therapy.
1 · March 8 at 11:03am
So, let's see what happens
I trust we'll come to love Remo rather than fear him.
All the while 7 Acres product lies in the vault unscathed and out of ears ;)
No doubt...I totally agree
sorry to bother you again mr.cheap, but you mentioned a ticker symbol "gappa" ...i can't seem to find it
...or were you trying say the English word "gap"?
just another addition yet to develop more strategies...
i'm waiting for the news that "really" matters
i'm waiting for the news of FDA, patient, and trial developments!!!
Go PMCB!!!
Yep...just hoping it helps with those second guessing ;)
Scratch that idea...just heard news...things should/will be fine. A reliable source says that John said there is NO pesticide in the Remo product he is using.
I don't use Facebook or Twitter, but if I did I would probably try and ask Sandra Colasanti if she could possibly shed any light on the matter. She's been there since they started out of their garage...she's his wife.